FDA Plans New Regulatory Guidance for Generative AI Tools
The agency aims to finalize policy after reviewing hundreds of public comments on medical device software standards.
Updated on Oct. 20, 2026 in Artificial Intelligence
Live Poll
Should government agencies regulate AI medical tools like human doctors rather than traditional software?
The FDA is preparing to issue draft policy guidance for regulating generative AI medical devices following a major public consultation. The move marks a pivot in oversight as the agency adapts to technologies that require more complex evaluation than traditional software.
Why it matters
Traditional software testing methods are insufficient for the unbounded evaluation space of generative AI, prompting the agency to prioritize new safety frameworks. This shift aims to ensure clinical judgment and patient safety remain central to the adoption of advanced medical AI.
The FDA has maintained a framework for software as a medical device for 20 years, but generative tools necessitate a shift toward evaluating clinical boundaries rather than binary outputs. The agency recently analyzed over 300 public comments to inform this transition.
The players
Rick Abramson
He serves as the director of the FDA's Digital Health Center of Excellence.
American Medical Association
The national professional association for physicians provided comments regarding the proposed regulatory framework.
FDA
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of medical devices.
The details
The agency is considering evaluating these tools similarly to how it assesses the competency of physicians. This approach seeks to move beyond testing specific software outputs to ensure the systems adhere to rigorous safety and clinical judgment standards.
Timeline
October 19, 2026: The public comment period for the FDA discussion paper closed.
October 20, 2026: Rick Abramson discussed regulatory policy at The MedTech Conference.
Upcoming months: The FDA expects to issue its draft policy guidance.
The Tech Race
The agency's new guidance marks a departure from the existing Software as a medical device regulatory framework by introducing clinical competency assessments. This transition reflects a broader industry shift toward testing AI systems for behavioral safety rather than static performance.
Healthcare providers and medical technology developers can expect clearer compliance pathways as the agency establishes new standards for clinical AI reliability. These changes will likely influence how medical facilities integrate new diagnostic and patient-support tools.
The takeaway
The move toward competency-based testing highlights that AI in medicine is being treated more like a human provider than a static calculator. Developers should focus on the transparency of their models' clinical logic to align with these anticipated regulatory standards.
Further reading
Learn more about the latest developments in Artificial Intelligence regulatory policy in the United States.
Source note: This article includes information reported by MedCity News.
Live Poll
Should government agencies regulate AI medical tools like human doctors rather than traditional software?
